U.S. Stocks Decline Midway, Dow Jones Falls Over 400 Points
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Should l Buy BMY?
Source: Benzinga
- U.S. Stock Weakness: Midway through trading on Thursday, U.S. stocks declined significantly, with the Dow Jones dropping over 400 points, a 0.86% decrease to 49,073.13, indicating investor concerns about the economic outlook.
- Sector Performance Divergence: While real estate shares gained slightly by 0.1%, materials stocks fell by 2.2%, reflecting varying investor confidence across sectors, which could influence future investment strategies.
- Bristol Myers Earnings Beat: Bristol Myers Squibb reported fourth-quarter 2025 revenues of $12.50 billion, surpassing the consensus estimate of $12.281 billion with a 1% year-over-year increase, demonstrating resilience in a competitive pharmaceutical market.
- Weak Employment Data: U.S. job openings fell by 386,000 to 6.542 million in December, below the market estimate of 7.2 million, while initial jobless claims rose by 22,000 to 231,000, indicating challenges in the economic recovery.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 62.370
Low
37.00
Averages
55.86
High
68.00
Current: 62.370
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol Myers Squibb: A High Dividend Investment Opportunity
- Dividend Yield Advantage: Bristol Myers Squibb currently offers a 4% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it an attractive option for income-seeking investors.
- Market Competition and Opportunities: Despite operating in a highly competitive pharmaceutical market, Bristol Myers Squibb focuses on cardiovascular, cancer, and immune-related drugs, which present substantial market potential, especially as GLP-1 weight-loss drugs gain attention.
- Price Recovery Potential: With a current stock price of $62.37, approximately 25% below its late 2022 highs, there is recovery potential for investors, and the company's 70% payout ratio indicates a solid commitment to maintaining dividends.
- Patent Protection and Growth Foundation: While Bristol Myers Squibb's Opdivo cancer drug will lose patent protection in 2028, the company is developing alternative delivery methods to extend its patent life, and its pipeline includes other drugs, showcasing its ongoing growth potential.
See More
Five Key Principles of Innovation
- Importance of Innovation Culture: Lorraine Marchand emphasizes that successful organizations foster a culture that reframes failure as a learning opportunity, encouraging experimentation and allowing employees to freely express new ideas, thereby enhancing the organization's innovative capacity.
- Investment Strategy in Risk: She notes that successful companies often follow a 70/20/10 investment ratio, with 10% allocated to uncertain innovation projects, a strategy validated by Google's success, indicating that appropriate risk investment can significantly drive company growth.
- Customer-First Strategy: Marchand points out that many companies fail to adjust to changing customer demands, leading to market failures; therefore, investors should focus on a company's customer-oriented strategies to avoid failures similar to those of Blockbuster and Kodak.
- Collaboration and Change Management: She highlights that collaboration has become a strategic imperative for corporate success, and organizations need to prioritize team collaboration during change to achieve breakthrough growth, ensuring that departments work together towards common objectives.
See More
Acute Ischemic Stroke Market Set for Growth Driven by Innovative Therapies
- Growth Drivers: The acute ischemic stroke market is expected to experience significant growth from 2026 to 2036, primarily driven by increased awareness of symptoms, advancements in acute stroke care, and a robust pipeline of new therapies, particularly lenzocimab, DM199, and milvexian.
- Market Size Forecast: By 2036, the acute ischemic stroke treatment market is projected to continue expanding, with the United States holding the largest market share; in 2025, approximately 1.8 million new cases of acute ischemic stroke are expected in the 7MM, indicating strong market demand.
- Clinical Progress of New Therapies: Several innovative acute ischemic stroke drugs are currently in clinical trials, including Acticor Biotech's Glenzocimab and DiaMedica Therapeutics' DM199, which are anticipated to transform the market landscape by providing more effective treatment options in the coming years.
- Challenges and Opportunities: While the acute ischemic stroke market faces challenges from high mortality and morbidity rates, the launch of new drugs and advancements in stem cell therapies present significant opportunities for pharmaceutical companies, likely driving long-term growth in the industry.
See More
FourWorld Capital Increases Stake in Sable Offshore Corp.
- Increased Holdings: FourWorld Capital Management LLC acquired 8,105,608 shares of Sable Offshore Corp. in Q4 2025, valued at $73.11 million, making it the fund's largest holding at 62.89% of AUM.
- Stock Performance: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, significantly underperforming the S&P 500 by 86.44 percentage points, indicating severe competitiveness issues in the market.
- Legal Challenges: Sable Offshore faces major legal hurdles; despite federal approval for the restart of its Las Flores pipeline in California, environmental groups filed lawsuits to halt it, and a recent court ruling against the company could increase stock volatility.
- Investment Risks: While the significant drop in Sable Offshore's stock price makes it a relatively cheap investment, its future success will heavily depend on resolving ongoing legal issues, categorizing it as a high-risk buy at this time.
See More
FourWorld Capital Management Acquires Major Stake in Sable Offshore Corp.
- New Investment Position: According to a February 17, 2026 SEC filing, FourWorld Capital Management acquired 8,105,608 shares of Sable Offshore Corp. valued at $73.11 million, making it the fund's largest holding at 62.9% of reportable AUM.
- Portfolio Structure Shift: As of December 31, 2025, Sable Offshore's holding value of $73.11 million significantly overshadows other holdings, with IWM and BMY making up less than 5%, indicating FourWorld's strong conviction in this investment.
- Stock Volatility Risk: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, facing legal challenges that could increase future stock volatility, necessitating cautious risk assessment by investors.
- Legal Challenges Impact: Although Sable Offshore received federal approval to restart its Las Flores pipeline in California, lawsuits from environmental groups and a judge's ruling against the restart hinder progress, with ongoing legal battles likely to directly affect the company's operations and stock performance.
See More
Middle East Turmoil Triggers Market Panic
- Oil Price Surge Impact: The closure of the Strait of Hormuz due to U.S. and Israeli attacks on Iran has led to skyrocketing oil prices, which are expected to exacerbate inflation and hinder the Federal Reserve's ability to cut interest rates, posing significant obstacles to economic recovery.
- Private Equity Crisis: Private equity and private credit firms are facing a trust crisis as they are perceived as high-risk debt bearers, leading to a sharp decline in market confidence regarding their future, which could result in a wave of bankruptcies and further heighten recession risks.
- Nvidia Under Customer Pressure: Despite Nvidia reporting strong quarterly results last week, concerns over future demand have intensified as competitors Amazon and Alphabet launched cheaper chips, causing its stock price to drop from $196 to $176, reflecting investor panic in the tech sector.
- Layoff Wave Triggers Market Turmoil: Block's announcement of a 40% workforce reduction has sparked concerns about the future of the tech industry; while this move may boost stock prices in the short term, it risks losing top talent and undermining operational stability and market confidence in the long run.
See More
Bristol Myers Squibb: A High Dividend Investment Opportunity
- Dividend Yield Advantage: Bristol Myers Squibb currently offers a 4% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it an attractive option for income-seeking investors.
- Market Competition and Opportunities: Despite operating in a highly competitive pharmaceutical market, Bristol Myers Squibb focuses on cardiovascular, cancer, and immune-related drugs, which present substantial market potential, especially as GLP-1 weight-loss drugs gain attention.
- Price Recovery Potential: With a current stock price of $62.37, approximately 25% below its late 2022 highs, there is recovery potential for investors, and the company's 70% payout ratio indicates a solid commitment to maintaining dividends.
- Patent Protection and Growth Foundation: While Bristol Myers Squibb's Opdivo cancer drug will lose patent protection in 2028, the company is developing alternative delivery methods to extend its patent life, and its pipeline includes other drugs, showcasing its ongoing growth potential.
See More
Five Key Principles of Innovation
- Importance of Innovation Culture: Lorraine Marchand emphasizes that successful organizations foster a culture that reframes failure as a learning opportunity, encouraging experimentation and allowing employees to freely express new ideas, thereby enhancing the organization's innovative capacity.
- Investment Strategy in Risk: She notes that successful companies often follow a 70/20/10 investment ratio, with 10% allocated to uncertain innovation projects, a strategy validated by Google's success, indicating that appropriate risk investment can significantly drive company growth.
- Customer-First Strategy: Marchand points out that many companies fail to adjust to changing customer demands, leading to market failures; therefore, investors should focus on a company's customer-oriented strategies to avoid failures similar to those of Blockbuster and Kodak.
- Collaboration and Change Management: She highlights that collaboration has become a strategic imperative for corporate success, and organizations need to prioritize team collaboration during change to achieve breakthrough growth, ensuring that departments work together towards common objectives.
See More
Acute Ischemic Stroke Market Set for Growth Driven by Innovative Therapies
- Growth Drivers: The acute ischemic stroke market is expected to experience significant growth from 2026 to 2036, primarily driven by increased awareness of symptoms, advancements in acute stroke care, and a robust pipeline of new therapies, particularly lenzocimab, DM199, and milvexian.
- Market Size Forecast: By 2036, the acute ischemic stroke treatment market is projected to continue expanding, with the United States holding the largest market share; in 2025, approximately 1.8 million new cases of acute ischemic stroke are expected in the 7MM, indicating strong market demand.
- Clinical Progress of New Therapies: Several innovative acute ischemic stroke drugs are currently in clinical trials, including Acticor Biotech's Glenzocimab and DiaMedica Therapeutics' DM199, which are anticipated to transform the market landscape by providing more effective treatment options in the coming years.
- Challenges and Opportunities: While the acute ischemic stroke market faces challenges from high mortality and morbidity rates, the launch of new drugs and advancements in stem cell therapies present significant opportunities for pharmaceutical companies, likely driving long-term growth in the industry.
See More
FourWorld Capital Increases Stake in Sable Offshore Corp.
- Increased Holdings: FourWorld Capital Management LLC acquired 8,105,608 shares of Sable Offshore Corp. in Q4 2025, valued at $73.11 million, making it the fund's largest holding at 62.89% of AUM.
- Stock Performance: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, significantly underperforming the S&P 500 by 86.44 percentage points, indicating severe competitiveness issues in the market.
- Legal Challenges: Sable Offshore faces major legal hurdles; despite federal approval for the restart of its Las Flores pipeline in California, environmental groups filed lawsuits to halt it, and a recent court ruling against the company could increase stock volatility.
- Investment Risks: While the significant drop in Sable Offshore's stock price makes it a relatively cheap investment, its future success will heavily depend on resolving ongoing legal issues, categorizing it as a high-risk buy at this time.
See More
FourWorld Capital Management Acquires Major Stake in Sable Offshore Corp.
- New Investment Position: According to a February 17, 2026 SEC filing, FourWorld Capital Management acquired 8,105,608 shares of Sable Offshore Corp. valued at $73.11 million, making it the fund's largest holding at 62.9% of reportable AUM.
- Portfolio Structure Shift: As of December 31, 2025, Sable Offshore's holding value of $73.11 million significantly overshadows other holdings, with IWM and BMY making up less than 5%, indicating FourWorld's strong conviction in this investment.
- Stock Volatility Risk: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, facing legal challenges that could increase future stock volatility, necessitating cautious risk assessment by investors.
- Legal Challenges Impact: Although Sable Offshore received federal approval to restart its Las Flores pipeline in California, lawsuits from environmental groups and a judge's ruling against the restart hinder progress, with ongoing legal battles likely to directly affect the company's operations and stock performance.
See More
Middle East Turmoil Triggers Market Panic
- Oil Price Surge Impact: The closure of the Strait of Hormuz due to U.S. and Israeli attacks on Iran has led to skyrocketing oil prices, which are expected to exacerbate inflation and hinder the Federal Reserve's ability to cut interest rates, posing significant obstacles to economic recovery.
- Private Equity Crisis: Private equity and private credit firms are facing a trust crisis as they are perceived as high-risk debt bearers, leading to a sharp decline in market confidence regarding their future, which could result in a wave of bankruptcies and further heighten recession risks.
- Nvidia Under Customer Pressure: Despite Nvidia reporting strong quarterly results last week, concerns over future demand have intensified as competitors Amazon and Alphabet launched cheaper chips, causing its stock price to drop from $196 to $176, reflecting investor panic in the tech sector.
- Layoff Wave Triggers Market Turmoil: Block's announcement of a 40% workforce reduction has sparked concerns about the future of the tech industry; while this move may boost stock prices in the short term, it risks losing top talent and undermining operational stability and market confidence in the long run.
See More
